Next Article in Journal
Taste Receptors: New Players in Sperm Biology
Next Article in Special Issue
STAT3 Post-Translational Modifications Drive Cellular Signaling Pathways in Prostate Cancer Cells
Previous Article in Journal
Advances in Therapeutic Implications of Inorganic Drug Delivery Nano-Platforms for Cancer
Previous Article in Special Issue
Roles of MicroRNA-34a in Epithelial to Mesenchymal Transition, Competing Endogenous RNA Sponging and Its Therapeutic Potential
Article Menu
Issue 4 (February-2) cover image

Export Article

Open AccessArticle

BCAS2 Enhances Carcinogenic Effects of Estrogen Receptor Alpha in Breast Cancer Cells

Departamento de Investigación Básica, Instituto Nacional de Cancerología, Av. San Fernando No. 22, Col. Sección XVI, 14080 Mexico City, Mexico
Programa de Doctorado en Ciencias Biomédicas, Universidad Nacional Autónoma de México, 04510 Mexico City, Mexico
Institut de Biología Molecular de Barcelona (IBMB-CSIC) Parc Científic de Barcelona, Barcelona, 08028 Cataluña, Spain
Author to whom correspondence should be addressed.
Int. J. Mol. Sci. 2019, 20(4), 966;
Received: 17 January 2019 / Revised: 11 February 2019 / Accepted: 21 February 2019 / Published: 22 February 2019
PDF [3646 KB, uploaded 22 February 2019]


Estrogen receptor alpha (ERα) has an established role in breast cancer biology. Transcriptional activation by ERα is a multistep process modulated by coactivator and corepressor proteins. Breast Cancer Amplified Sequence 2 (BCAS2), is a poorly studied ERα coactivator. In this work, we characterize some of the mechanisms through which this protein increases ERα activity and how this promotes carcinogenic processes in breast cancer cells. Using protein-protein interaction and luciferase assays we show that BCAS2 interacts with ERα both in vitro and in vivo and upregulates transcriptional activation of ERα directly through its N-terminal region (AF-1) and indirectly through its C-terminal (AF-2) region, acting in concert with AF-2 interacting coactivators. Elevated expression of BCAS2 positively affects proliferation, clonogenicity and migration of breast cancer cells and directly activates ERα regulated genes which have been shown to play a role in tumor growth and progression. Finally, we used signal transduction pathway inhibitors to elucidate how BCAS2 is regulated in these cells and observed that BCAS2 is preferentially regulated by the PI3K/AKT signaling pathway. BCAS2 is an AF-1 coactivator of ERα whose overexpression promotes carcinogenic processes, suggesting an important role in the development of estrogen-receptor positive breast cancer. View Full-Text
Keywords: estrogen receptor; breast cancer; BCAS2; coactivators estrogen receptor; breast cancer; BCAS2; coactivators

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).

Supplementary material


Share & Cite This Article

MDPI and ACS Style

Salmerón-Hernández, Á.; Noriega-Reyes, M.Y.; Jordan, A.; Baranda-Avila, N.; Langley, E. BCAS2 Enhances Carcinogenic Effects of Estrogen Receptor Alpha in Breast Cancer Cells. Int. J. Mol. Sci. 2019, 20, 966.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Int. J. Mol. Sci. EISSN 1422-0067 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top